Clinical Trial

Unveiling the Germline Predisposition to Myeloproliferative Neoplasms

Recruiting
View on ClinicalTrials.gov →
Summary
The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK/STAT signal transduction because of acquired somatic mutations of JAK2, CALR or MPL genes. They are sporadic diseases but there are several lines of evidence that support the role of germline factors in the pathogenesis of MPN: the existence of familial clustering, the presence of more than one clone in some patients, the known existence of common polymorphisms that cause predisposition to MPN. In this study, we would like to define the germline predisposition to MPN.
Trial Details
NCT Number NCT07204392
Lead Sponsor Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions Myeloproliferative Disease, Germline Mutation
Enrollment 313 participants
Start Date 2022-06-27
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-02